title: Genetically engineered T cells for the treatment of cancer.
abstract: T-cell immunotherapy is a promising approach to treat disseminated cancer. However, it has been limited by the ability to isolate and expand T cells restricted to tumour-associated antigens. Using ex vivo gene transfer, T cells from patients can be genetically engineered to express a novel T cell receptor or chimeric antigen receptor to specifically recognize a tumour-associated antigen and thereby selectively kill tumour cells. Indeed, genetically engineered T cells have recently been successfully used for cancer treatment in a small number of patients. Here we review the recent progress in the field, and summarize the challenges that lie ahead and the strategies being used to overcome them.
authors.affiliation: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. magnus.essand@igp.uu.se
authors.forename: M
authors.initials: M
authors.lastname: Essand
authors.forename: A S I
authors.initials: AS
authors.lastname: Loskog
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D002986:Clinical Trials as Topic; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000502:physiology*
chemical_list: D000951:Antigens, Neoplasm